Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

198P - Association between BTLA polymorphisms and NSCLC risk


03 Apr 2022


Poster Display session


Tumour Site

Non-Small Cell Lung Cancer


Anna Andrzejczak


Annals of Oncology (2022) 33 (suppl_2): S117-S121. 10.1016/annonc/annonc858


A. Andrzejczak1, A. Partyka1, A. Wisniewski1, I. Porebska2, K. Pawelczyk3, M. Jasek1, L. Karabon1

Author affiliations

  • 1 Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw/PL
  • 2 Wroclaw Medical University, Wroclaw/PL
  • 3 Lower Silesian Centre of Lung Diseases, Wroclaw/PL

Abstract 198P


Importance of immune checkpoints molecules in NSCLC was proven by the introduction of blockade of these receptors in routine treatment. B and T lymphocyte attenuator (BTLA) is another immune checkpoint molecule that regulates immune response. Our previous studies showed a significant association between BTLA gene variants and susceptibility to renal cell carcinoma and chronic lymphoblastic leukemia. The aim of this study was to verify the hypothesis that BTLA polymorphic variants are associated with susceptibility to NSCLC.


Genomic DNA was isolated from the venous blood of 384 patients diagnosed with NSCLC and 475 controls. Using TaqMan probes we genotyped seven BTLA SNPs: rs1982809, rs1844089, rs9288952, rs9288953, rs2705511, rs2633582, and rs11921669 on ViiA 7 Real-Time PCR System.


Statistical analysis of genotypes and alleles distributions for all investigated BTLA SNPs showed that SNP rs1982809 may be associated with susceptibility to NSCLC. In particular presence of G allele at rs1982809 (AG+GG genotypes) was more frequent in NSCLC group compared to controls (38.8% vs 45.3%, p=0.056). Allele distribution showed that the presence of allele G in rs1982809 significantly increases NSCLC risk (OR=1.25, p=0.046). For other studied SNPs in the overall analysis, we did not observe differences between NSCLC patients and controls. However, in the subgroup analysis we found that in patients with adenocarcinoma (AD) genotypes distribution of rs1982809 was significantly different between AD patients and controls (p=0.048). Moreover, we noticed the trend for overrepresentation of rs2705511[C] allele (AC+CC genotypes) in patients with AD compared to controls (43.4% vs 53%, p=0.079). After stratification by gender, we observed an association between the presence of rs9288953[T] and NSCLC susceptibility (p=0.004) in females. The global distributions of the haplotypes did not differ significantly between the cases and controls. However, we noticed that the global distribution of the haplotypes differs significantly between the never-smokers and smokers (p=0.0003).


Results of our study show that rs1982809 in BTLA gene might be considered a low penetrating risk factor for NSCLC susceptibility in the Polish population.

Legal entity responsible for the study

Laboratory of Genetics and Epigenetics of Human Diseases.


National Science Center Poland OPUS17 2019/33/B/NZ5/03029.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.